Trial Profile
A phase I/II study of the safety and tolerability of DTI-015 [carmustine] in patients with recurrent glioblastoma multiforme
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Carmustine (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 01 Nov 2007 Status changed from suspended to in progress.
- 05 Oct 2005 New trial record.